{"id":"durvalumab-plus-chemotherapy","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Fatigue"},{"rate":"30-40","effect":"Nausea"},{"rate":"25-35","effect":"Decreased appetite"},{"rate":"3-5","effect":"Immune-mediated pneumonitis"},{"rate":"2-4","effect":"Immune-mediated hepatitis"},{"rate":"20-30","effect":"Anemia"},{"rate":"15-25","effect":"Neutropenia"},{"rate":"15-25","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3301587","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Durvalumab is a PD-L1 inhibitor that prevents tumor cells from suppressing T-cell responses, thereby reinvigorating anti-tumor immunity. Chemotherapy acts as a cytotoxic agent that kills cancer cells and can promote immunogenic cell death, making tumor antigens more available to the immune system. The combination leverages both direct cytotoxic effects and immune checkpoint blockade for enhanced therapeutic benefit.","oneSentence":"Durvalumab blocks PD-L1 to restore anti-tumor immunity, while chemotherapy directly kills cancer cells and enhances immune activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:16.790Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unresectable stage III non-small cell lung cancer (NSCLC)"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Advanced or metastatic urothelial carcinoma"}]},"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma","enrollment":70},{"nctId":"NCT05198830","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-15","conditions":"Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":42},{"nctId":"NCT07036380","phase":"PHASE2","title":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-12-22","conditions":"Advanced Biliary Tract Carcinoma","enrollment":75},{"nctId":"NCT04351256","phase":"PHASE2","title":"Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2020-05-20","conditions":"NSCLC, Stage III","enrollment":51},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT02537418","phase":"PHASE1","title":"Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-16","conditions":"Solid Malignancies","enrollment":153},{"nctId":"NCT05411094","phase":"PHASE1","title":"Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-22","conditions":"Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":18},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT06058377","phase":"PHASE3","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-27","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma","enrollment":3680},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT02997332","phase":"PHASE1","title":"Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-03-30","conditions":"Head and Neck Cancers","enrollment":14},{"nctId":"NCT06467357","phase":"PHASE3","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-12","conditions":"Biliary Tract Cancer","enrollment":620},{"nctId":"NCT07221253","phase":"PHASE3","title":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-04","conditions":"Biliary Tract Cancer","enrollment":1100},{"nctId":"NCT06284317","phase":"PHASE3","title":"A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.","status":"RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2025-01-15","conditions":"Non Small Cell Lung Cancer","enrollment":290},{"nctId":"NCT04499053","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2020-12-09","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":18},{"nctId":"NCT06667908","phase":"PHASE2","title":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2024-12-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":130},{"nctId":"NCT03732677","phase":"PHASE3","title":"Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-16","conditions":"Muscle Invasive Bladder Cancer","enrollment":1063},{"nctId":"NCT07332351","phase":"PHASE2","title":"Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-06-01","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":33},{"nctId":"NCT04301778","phase":"PHASE2","title":"Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-08-24","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":5},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT05687266","phase":"PHASE3","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-29","conditions":"NSCLC","enrollment":1350},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT03003962","phase":"PHASE3","title":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-01-02","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":669},{"nctId":"NCT05061550","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-04-14","conditions":"Non-small Cell Lung Cancer","enrollment":630},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT07459634","phase":"PHASE2","title":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","status":"NOT_YET_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2026-04-25","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":50},{"nctId":"NCT03660826","phase":"PHASE2","title":"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-27","conditions":"Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma","enrollment":288},{"nctId":"NCT06859684","phase":"PHASE2","title":"Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-03-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab","enrollment":25},{"nctId":"NCT04900818","phase":"PHASE1","title":"Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"I-Mab Biopharma US Limited","startDate":"2021-06-29","conditions":"Solid Tumor, Advanced Cancer, Metastatic Cancer","enrollment":330},{"nctId":"NCT05941897","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-06-21","conditions":"Advanced or Metastatic NSCLC","enrollment":39},{"nctId":"NCT02812420","phase":"EARLY_PHASE1","title":"Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-03-07","conditions":"Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant","enrollment":54},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT05068232","phase":"PHASE2","title":"Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2022-08-19","conditions":"Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer","enrollment":49},{"nctId":"NCT03057106","phase":"PHASE2","title":"Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2017-03-28","conditions":"Lung Cancer Metastatic","enrollment":301},{"nctId":"NCT02453282","phase":"PHASE3","title":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-07-21","conditions":"Non-Small-Cell Lung Carcinoma NSCLC","enrollment":1118},{"nctId":"NCT04068610","phase":"PHASE1, PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":"Metastatic Microsatellite-stable Colorectal Cancer","enrollment":61},{"nctId":"NCT06103864","phase":"PHASE3","title":"A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-23","conditions":"Breast Cancer","enrollment":625},{"nctId":"NCT04602533","phase":"PHASE2","title":"Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Hopp","startDate":"2020-12-21","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":105},{"nctId":"NCT06078709","phase":"PHASE2","title":"Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-20","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8","enrollment":99},{"nctId":"NCT04945720","phase":"PHASE2","title":"Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-04-11","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05683977","phase":"","title":"A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-11-14","conditions":"Small Cell Lung Carcinoma","enrollment":254},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":"Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer","enrollment":39},{"nctId":"NCT06960577","phase":"PHASE3","title":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-15","conditions":"Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate","enrollment":150},{"nctId":"NCT02264678","phase":"PHASE1, PHASE2","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-10-31","conditions":"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer","enrollment":357},{"nctId":"NCT04892953","phase":"PHASE2","title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-07","conditions":"Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8","enrollment":51},{"nctId":"NCT05403723","phase":"PHASE1","title":"Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC","status":"SUSPENDED","sponsor":"University of Maryland, Baltimore","startDate":"2026-06-30","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":50},{"nctId":"NCT05137262","phase":"PHASE2","title":"A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-13","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":12},{"nctId":"NCT06890273","phase":"","title":"NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-20","conditions":"Endometrial Cancer","enrollment":150},{"nctId":"NCT02542293","phase":"PHASE3","title":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-11-03","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":953},{"nctId":"NCT03819465","phase":"PHASE1","title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-27","conditions":"Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":175},{"nctId":"NCT06494540","phase":"","title":"NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-28","conditions":"Non-squamous Metastatic Non-Small-Cell Lung Carcinoma","enrollment":600},{"nctId":"NCT04585477","phase":"PHASE2","title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-04-08","conditions":"Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II","enrollment":80},{"nctId":"NCT03775486","phase":"PHASE2","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer NSCLC","enrollment":401},{"nctId":"NCT03965468","phase":"PHASE2","title":"Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-11-19","conditions":"Non-small Cell Lung Cancer, Stage IV, Oligometastasis","enrollment":96},{"nctId":"NCT03851614","phase":"PHASE2","title":"Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-04-08","conditions":"Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma","enrollment":90},{"nctId":"NCT06904170","phase":"PHASE2, PHASE3","title":"Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Hepatocellular Carcinoma","enrollment":196},{"nctId":"NCT03682068","phase":"PHASE3","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-09-27","conditions":"Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer","enrollment":1246},{"nctId":"NCT04999969","phase":"PHASE2","title":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-12-10","conditions":"Locally Advanced or Metastatic Solid Tumours","enrollment":126},{"nctId":"NCT05925530","phase":"PHASE2","title":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-22","conditions":"Non-small Cell Lung Cancer","enrollment":142},{"nctId":"NCT06634199","phase":"","title":"Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2024-10-03","conditions":"Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation","enrollment":50},{"nctId":"NCT05223647","phase":"PHASE3","title":"Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer","status":"TERMINATED","sponsor":"Norwegian University of Science and Technology","startDate":"2022-01-11","conditions":"Small-cell Lung Cancer","enrollment":239},{"nctId":"NCT07229625","phase":"PHASE3","title":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-01-21","conditions":"Advanced Biliary Tract Cancer","enrollment":604},{"nctId":"NCT02516241","phase":"PHASE3","title":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-11-02","conditions":"Urothelial Cancer","enrollment":1126},{"nctId":"NCT06810609","phase":"PHASE2","title":"Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC","status":"RECRUITING","sponsor":"University Hospital, Bonn","startDate":"2025-04-20","conditions":"Lung Cancer Non-Small Cell Cancer (NSCLC)","enrollment":176},{"nctId":"NCT07364305","phase":"PHASE2","title":"HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC","status":"RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2025-01-01","conditions":"ICC, Advanced Cancer","enrollment":50},{"nctId":"NCT04781192","phase":"PHASE1, PHASE2","title":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-03-22","conditions":"Advanced Biliary Tract Cancer","enrollment":40},{"nctId":"NCT04334759","phase":"PHASE3","title":"DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma","status":"COMPLETED","sponsor":"PrECOG, LLC.","startDate":"2021-02-18","conditions":"Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma","enrollment":214},{"nctId":"NCT06591520","phase":"PHASE3","title":"AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2024-10-20","conditions":"Biliary Tract Cancer","enrollment":682},{"nctId":"NCT03778957","phase":"PHASE3","title":"A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-30","conditions":"Hepatocellular Carcinoma","enrollment":724},{"nctId":"NCT06746116","phase":"PHASE3","title":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-30","conditions":"Advanced or Recurrent Endometrial Cancer","enrollment":45},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03923270","phase":"PHASE1","title":"Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-06","conditions":"Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer","enrollment":25},{"nctId":"NCT04607954","phase":"PHASE2","title":"Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-12-04","conditions":"Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma","enrollment":29},{"nctId":"NCT04699838","phase":"PHASE2","title":"Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Muhammad Furqan","startDate":"2021-04-20","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07247786","phase":"PHASE2","title":"Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)","status":"NOT_YET_RECRUITING","sponsor":"Fundación GECP","startDate":"2026-03-15","conditions":"Non Small Cell Lung Cancer, Respiratory Tract Neoplasm","enrollment":68},{"nctId":"NCT04592913","phase":"PHASE3","title":"Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-17","conditions":"Gastrointestinal Neoplasms, Esophagogastric Junction","enrollment":957},{"nctId":"NCT04711824","phase":"PHASE1, PHASE2","title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"Colette Shen","startDate":"2022-03-09","conditions":"Breast Cancer, Brain Metastases, Adult","enrollment":41},{"nctId":"NCT04269200","phase":"PHASE3","title":"Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-05-05","conditions":"Endometrial Neoplasms","enrollment":805},{"nctId":"NCT04728230","phase":"PHASE1, PHASE2","title":"Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-05","conditions":"Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":63},{"nctId":"NCT04612751","phase":"PHASE1","title":"Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-02-02","conditions":"Advanced or Metastatic NSCLC","enrollment":155},{"nctId":"NCT02726997","phase":"PHASE1, PHASE2","title":"Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-07-06","conditions":"Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7","enrollment":18},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT06102057","phase":"PHASE2","title":"PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC","status":"RECRUITING","sponsor":"TheraOp","startDate":"2024-07-01","conditions":"Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable","enrollment":110},{"nctId":"NCT04765709","phase":"PHASE2","title":"Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-09-24","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":10},{"nctId":"NCT05733598","phase":"PHASE2","title":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT04745689","phase":"PHASE2","title":"Study of AZD2811 + Durvalumab in ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-02-23","conditions":"Small-Cell Lung Cancer","enrollment":31},{"nctId":"NCT04163432","phase":"PHASE2","title":"Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2020-06-16","conditions":"Non-Small Cell Lung Cancer Metastatic","enrollment":43},{"nctId":"NCT03249142","phase":"PHASE1, PHASE2","title":"Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2017-10-18","conditions":"Ovarian Cancer","enrollment":69},{"nctId":"NCT05568212","phase":"PHASE2","title":"Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2022-05-02","conditions":"Non-small-cell Lung Cancer Patients","enrollment":176},{"nctId":"NCT03999710","phase":"PHASE2","title":"Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-07-19","conditions":"Non Small Cell Lung Cancer, Lung Cancer, Nsclc","enrollment":61},{"nctId":"NCT05450692","phase":"PHASE3","title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-15","conditions":"Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":594},{"nctId":"NCT04686305","phase":"PHASE1","title":"Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-03-09","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":244},{"nctId":"NCT04216290","phase":"PHASE2","title":"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":89,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Durvalumab plus chemotherapy","genericName":"Durvalumab plus chemotherapy","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Durvalumab blocks PD-L1 to restore anti-tumor immunity, while chemotherapy directly kills cancer cells and enhances immune activation. Used for Unresectable stage III non-small cell lung cancer (NSCLC), Metastatic non-small cell lung cancer, Advanced or metastatic urothelial carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}